Matthew R Russell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3679459/publications.pdf

Version: 2024-02-01

858243 1113639 16 689 12 15 citations h-index g-index papers 16 16 16 1110 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Generation of a mouse SWATH-MS spectral library to quantify 10148 proteins involved in cell reprogramming. Scientific Data, 2021, 8, 118.	2.4	4
2	Altered protein O-GlcNAcylation in placentas from mothers with diabetes causes aberrant endocytosis in placental trophoblast cells. Scientific Reports, 2021, 11, 20705.	1.6	7
3	Characterization of CYP2B6 K262R allelic variants by quantitative allele-specific proteomics using a QconCAT standard. Journal of Pharmaceutical and Biomedical Analysis, 2020, 178, 112901.	1.4	7
4	Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. British Journal of Cancer, 2019, 121, 483-489.	2.9	32
5	Cytoplasmic glycosylation of clathrin-mediated endocytosis signalling components alters the rate of iron uptake by placenta of mothers with type 2 diabetes. Placenta, 2017, 57, 300-301.	0.7	O
6	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. British Journal of Cancer, 2017, 117, 666-674.	2.9	47
7	Novel risk models for early detection and screening of ovarian cancer. Oncotarget, 2017, 8, 785-797.	0.8	13
8	Protein Z: A putative novel biomarker for early detection of ovarian cancer. International Journal of Cancer, 2016, 138, 2984-2992.	2.3	41
9	In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition. Drug Metabolism and Disposition, 2016, 44, 476-480.	1.7	33
10	In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells. Drug Metabolism and Disposition, 2016, 44, 297-307.	1.7	50
11	Application of an LC–MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique. Journal of Pharmaceutical and Biomedical Analysis, 2015, 110, 27-33.	1.4	53
12	Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics. Drug Metabolism and Disposition, 2014, 42, 1766-1772.	1.7	35
13	Simultaneous Quantification of the Abundance of Several Cytochrome P450 and Uridine 5′-Diphospho-Glucuronosyltransferase Enzymes in Human Liver Microsomes Using Multiplexed Targeted Proteomics. Drug Metabolism and Disposition, 2014, 42, 500-510.	1.7	143
14	Alternative Fusion Protein Strategies to Express Recalcitrant QconCAT Proteins for Quantitative Proteomics of Human Drug Metabolizing Enzymes and Transporters. Journal of Proteome Research, 2013, 12, 5934-5942.	1.8	52
15	Pipeline to assess the greatest source of technical variance in quantitative proteomics using metabolic labelling. Journal of Proteomics, 2012, 77, 441-454.	1.2	20
16	Experimental and Statistical Considerations to Avoid False Conclusions in Proteomics Studies Using Differential In-gel Electrophoresis. Molecular and Cellular Proteomics, 2007, 6, 1354-1364.	2.5	152